AbbVie extends Rinvoq exclusivity by four years after generics settlements
AbbVie has signed deals with Rinvoq generic hopefuls as it extends protection for one of its prized assets until 2037.
Autoimmune Disorders
Otsuka to acquire Cantargia’s CAN10 for autoimmune diseases
IGI and AbbVie sign licence deal for cancer and autoimmune therapy
Sanofi’s riliprubart gains ODD status from Japan’s MHLW for CIDP
Vor Bio back from brink with autoimmune drug deal rising to $4bn
US FDA approves GSK’s Benlysta autoinjector for lupus nephritis
Harbour BioMed partners Otsuka on new T-cell therapy
Vertex halts development of diabetes cell therapy after trial failure
